Extending the perspective on left ventricular assist device pump thrombosis to left ventricular assist device system thrombosis

Robert L. Kormos, MD

The ability to return to a normal lifestyle with minimal malfunctions after having a left ventricular assist device (LVAD) implanted is based on the reliability of the pump and its components. It is an important part of improved quality of life.

The incidence of pump thrombosis in durable rotary LVADs varies between 7% and 14%, depending on the type of rotary pump and the era of implantation.1 This problem relates to hemocompatibility, and risk factors include a combination of patient characteristics, engineering design factors of the pumping components, and procedural or management issues.2 The HeartMate 3 (Thoratec Corporation, Pleasanton, Calif) uses engineering solutions that have obviated reports of pump thrombosis seen in other rotary pumps.3 In all clinical trials with LVADs and in recent reports with large registries (INTERMACS), the definition of pump thrombosis is based on biochemical testing that reflects elevated lactate dehydrogenase or plasma free hemoglobin, along with power and flow profiles that suggest increased resistance to rotor operation.4 These reports focus on pump thrombosis that is specific to the internal rotary mechanism and does not delineate a subset of thrombosis that is specific to the pump inflow or outflow cannulas or grafts. This information has not been collected in a granular fashion and if these latter components were included, it is not known what the global rates of LVAD system thrombosis would be for any LVAD.

The report in this issue of the Journal by Gruger and colleagues5 describes thrombosis in the potential space between the LVAD outflow graft and its external bend relief. Another report of outflow graft obstruction occurred during the CE Mark trial with the HeartMate 3, but the underlying mechanism was unclear. Another report of 2 cases of outflow graft occlusion in the HeartMate 3, from Duero Posada and colleagues6 at the Toronto General Hospital, describes outflow graft occlusion secondary to the collection of thrombotic material between the graft and the bend relief. As in this report of Gruger and colleagues,5 those cases occurred late after surgery, at 6 months and at 1 year.6 Duero Posada and colleagues6 hypothesize that transudate or blood leaking into the virtual space between the outflow graft and the bend relief resulted in lumen occlusion. The
bend relief in the HeartMate II is of a similar configuration as the HeartMate 3, and 2 reports exist of such outflow graft occlusion seen within the bend relief segment of the HeartMate II outflow graft, with delayed compromise of flow at 2 and 2.5 years after implantation.\textsuperscript{7,8} In these cases, the obstruction was resolved with an intravascular stent. Indeed, there are reports of outflow graft occlusion occurring secondary to graft compression with thrombus trapped under polytetrafluoroethylene wrapping used to reduce adhesions during the subsequent heart transplant.

This case report of Grüger and colleagues\textsuperscript{5} emphasizes the importance of detailed documentation of adverse events regarding modes of LVAD malfunction. These events may not be reported in clinical trials, because they occur beyond the initial study follow-up period, nor are they clearly incorporated into existing registries, such as INTERMACS. LVAD surgery is characterized by major interinstitutional variability; this was discovered in the HeartMate II post-market experience in relation to pump thrombosis but is not exclusive to that manufacturer.\textsuperscript{9} How these variations in technique effect such events is again poorly documented. The design of data collection in postmarket registries is critical to the understanding of long-term success or failure with these devices. Knowledge of whether this complication is a result of variable surgical technique, inherent physiologic reactions of patients, or a lack of robustness of design of the technology can only come from a deep examination and root cause analysis of evidence obtained from carefully collected real-world data.

References